Related Experiment Video
Updated: Aug 15, 2026

10:27
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
BG-9928 (Biogen Idec)
1Division of Health Practice, Auckland University of Technology-Akoranga Campus, Auckland, New Zealand. sdoggrell@xtra.co.nz
Abstract:
Biogen Idec, under license from CV Therapeutics, is developing BG-9928, a selective oral adenosine A, receptor antagonist, for the potential treatment of congestive heart failure. By January 2003, phase II trials of BG-9928 were ongoing.

